Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 68 Recurrence 7 Smoldering Multiple Myeloma 4 Neoplasms 4 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Plasmablastic Lymphoma 2 Lymphoma 2 Leukemia, Myeloid, Acute 2 Immunoglobulin Light-chain Amyloidosis 2 Plasmacytoma 1 Paraproteinemias 1 Neoplasms, Plasma Cell 1 Myelodysplastic Syndromes 1 Lymphoma, Large B-Cell, Diffuse 1 Leukemia, Plasma Cell 1 Glioblastoma 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 121 pembrolizumab 119 Pemetrexed 102 Cisplatin 76 Paclitaxel 56 osimertinib 52 Nivolumab 50 Docetaxel 50 durvalumab 47 Specimen Handling 37 Gemcitabine 34 Magnetic Resonance Spectroscopy 33 Radiosurgery 27 Cetuximab 26 130-nm albumin-bound paclitaxel 26 atezolizumab 25 Radiotherapy 20 Ipilimumab 19 Drug Therapy 19 Bevacizumab 19 cemiplimab 17 amivantamab 17 Taxes 16 Ramucirumab 13 alectinib 12 tislelizumab 11 lazertinib 11 Leucovorin 11 Fluorouracil 11 Radiation 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Non-Small-Cell Lung × daratumumab × 90 days × Clear all

NCT06015724 2026-05-15

DARANIVOVAX

Georgetown University

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡